Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 6, 2013, Pages 849-856

  Park, Jinsung ^a   Song, Cheryn ^b   Shin, Eunah ^c   Hong, Jun Hyuk ^b   Kim, Choung Soo ^b   Ahn, Hanjong ^b  

^a Eulji University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD9 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUSCLE TISSUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

BACILLUS CALMETTE-GUERIN; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; URINARY BLADDER NEOPLASM;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84880698009     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.06.004     Document Type: Article

References (47)

1. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178: 2314-2330.
2. Lebret T., Gaudez F., Herve J.M., et al. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: Recurrence, progression and success. Eur Urol 1998, 34: 67-72.
3. Manoharan M., Soloway M.S. Optimal management of the T1G3 bladder cancer. Urol Clin North Am 2005, 32: 133-145.
4. Baniel J., Grauss D., Engelstein D., et al. Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998, 52: 785-789.
5. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-Year outcome. Br J Urol 1997, 80: 762-765.
6. Zhang G.K., Uke E.T., Sharer W.C., et al. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 1996, 155: 1907-1909.
7. Patard J.J., Rodriguez A., Leray E., et al. Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 2002, 41: 635-641.
8. Denzinger S., Fritsche H.M., Otto W., et al. Early vs. deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach?. Eur Urol 2008, 53: 146-152.
9. Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 2001, 166: 1296-1299.
10. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49: 466-475.
11. Hurle R., Losa A., Manzetti A., et al. Intravesical bacillus Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: A 7-year follow-up. Urology 1999, 54: 258-263.
12. Park J., Song C., Hong J.H., et al. Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol 2009, 27: 277-283.
13. Solsona E., Iborra I., Dumont R., et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000, 164: 685-689.
14. Pansadoro V., Emiliozzi P., de Paula F., et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guerin: 18-Year experience. Urology 2002, 59: 227-231.
15. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4: 844-847.
16. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004, 22: 1014-1024.
17. Shariat S.F., Ashfaq R., Sagalowsky A.I., et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007, 177: 481-487.
18. Cote R.J., Dunn M.D., Chatterjee S.J., et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998, 58: 1090-1094.
19. Wu T.T., Chen J.H., Lee Y.H., et al. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000, 163: 758-760.
20. Zlotta A.R., Noel J.C., Fayt I., et al. Correlation and prognostic significance of p53, p21WAF1/CIP1, and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999, 161: 792-798.
21. Santos L., Amaro T., Costa C., et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 2003, 105: 267-272.
22. Blanchet P., Droupy S., Eschwege P., et al. Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma. Eur Urol 2001, 40: 169-175.
23. Mhawech-Fauceglia P., Cheney R.T., Fischer G., et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006, 32: 231-237.
24. Liedberg F., Anderson H., Chebil G., et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail?. Urol Oncol 2008, 26: 17-24.
25. Wang D.S., Rieger-Christ K., Latini J.M., et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 2000, 88: 620-625.
26. Tanaka M., Grossman H.B. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, down-regulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther 2003, 10: 1636-1642.
27. Mhawech P., Herrmann F., Coassin M., et al. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 2003, 98: 1649-1657.
28. Han K.S., Jeong I.G., Joung J.Y., et al. Clinical value of PTEN in patients with superficial bladder cancer. Urol Int 2008, 80: 264-269.
29. Ovesen H., Horn T., Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation. J Urol 1997, 157: 1655-1659.
30. Peyromaure M., Weibing S., Sebe P., et al. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology 2002, 59: 409-413.
31. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: The role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004, 45: 606-612.
32. Grossman H.B., Liebert M., Antelo M., et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998, 4: 829-834.
33. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004, 22: 1007-1013.
34. Caliskan M., Turkeri L.N., Mansuroglu B., et al. Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 1997, 79: 373-377.
35. Lebret T., Becette V., Barbagelatta M., et al. Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998, 159: 788-791.
36. Hainaut P., Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 2000, 77: 81-137.
37. Abdel-Fattah R., Challen C., Griffiths T.R., et al. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998, 77: 2230-2238.
38. Cordon-Cardo C., Wartinger D., Petrylak D., et al. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 1992, 84: 1251-1256.
39. Cormio L., Tolve I., Annese P., et al. Retinoblastoma protein expression predicts response to bacillus Calmette-Guerin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 2010, 28: 285-289.
40. Wolf H.K., Stober C., Hohenfellner R., et al. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumor Biol 2001, 22: 328-336.
41. Lebret T., Becette V., Herve J.M., et al. Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000, 37: 654-659.
42. van Rhijn B.W., van der Kwast T.H., Vis A.N., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004, 64: 1911-1914.
43. Bakkar A.A., Wallerand H., Radvanyi F., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003, 63: 8108-8112.
44. Hernandez S., Lopez-Knowles E., Lloreta J., et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 2005, 11: 5444-5450.
45. Lamy A., Gobet F., Laurent M., et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006, 176: 2686-2689.
46. Nocito A., Bubendorf L., Tinner E.M., et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001, 194: 349-357.
47. Bohle A., Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003, 170: 964-969.